During the last session, Solid Biosciences Inc (NASDAQ:SLDB)’s traded shares were 0.4 million, with the beta value of the company hitting 2.00. At the end of the trading day, the stock’s price was $5.41, reflecting an intraday gain of 3.44% or $0.18. The 52-week high for the SLDB share is $15.05, that puts it down -178.19 from that peak though still a striking 54.9% gain since the share price plummeted to a 52-week low of $2.44. The company’s market capitalization is $216.15M, and the average intraday trading volume over the past 10 days was 0.36 million shares, and the average trade volume was 280.13K shares over the past three months.
Solid Biosciences Inc (SLDB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.11. SLDB has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.76.
Solid Biosciences Inc (NASDAQ:SLDB) trade information
Solid Biosciences Inc (SLDB) registered a 3.44% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.44% in intraday trading to $5.41, hitting a weekly high. The stock’s 5-day price performance is 11.55%, and it has moved by -3.22% in 30 days. Based on these gigs, the overall price performance for the year is 106.49%. The short interest in Solid Biosciences Inc (NASDAQ:SLDB) is 1.48 million shares and it means that shorts have 4.44 day(s) to cover.
The consensus price target of analysts on Wall Street is $19, which implies an increase of 71.53% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $20 respectively. As a result, SLDB is trading at a discount of -269.69% off the target high and -121.81% off the low.
Solid Biosciences Inc (SLDB) estimates and forecasts
Statistics show that Solid Biosciences Inc has outperformed its competitors in share price, compared to the industry in which it operates. Solid Biosciences Inc (SLDB) shares have gone down -30.55% during the last six months, with a year-to-date growth rate more than the industry average at 40.99% against 17.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 24.14% this quarter and then drop -6.25% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 32.21%. While earnings are projected to return 42.24% in 2024.
SLDB Dividends
Solid Biosciences Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Solid Biosciences Inc (NASDAQ:SLDB)’s Major holders
Solid Biosciences Inc insiders own 0.82% of total outstanding shares while institutional holders control 90.07%, with the float percentage being 90.81%.
Also, the Mutual Funds coming in first place with the largest holdings of Solid Biosciences Inc (SLDB) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 854.68 shares. This amounts to just over 2.14 percent of the company’s overall shares, with a $4.62 million market value. The same data shows that the other fund manager holds slightly less at 605.96, or about 1.52% of the stock, which is worth about $3.28 million.
